APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

被引：0
|
作者：
Necchi, A. [1 ]
Mariani, L. [2 ]
Anichini, A. [3 ]
Giannatempo, P. [1 ]
Raggi, D. [1 ]
Togliardi, E. [4 ]
Calareso, G. [5 ]
Di Genova, N. [1 ]
Crippa, F. [6 ]
Salvioni, R. [7 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Clin Epidemiol & Trials Org Unit, Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Expt Oncol & Mol Med, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Pharm Unit, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Radiol, Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Nucl Med & PET Unit, Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Surg Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw373.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A randomized, open-label, phase II study of CC-486 (oral azacitidine), alone or in combination with durvalumab (MEDI4736), in patients (pts) with myelodysplastic syndromes (MDS) unresponsive to prior parenteral azacitidine or decitabine.
    Fenaux, Pierre
    Silverman, Lewis R.
    Mufti, Ghulam J.
    Seymour, John Francis
    Komrokji, Rami S.
    Faderl, Stefan
    Lam, Du Hung
    Sharr-McMahon, Michele
    Beach, C. L.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).
    Rajan, Arun
    Heery, Christopher Ryan
    Perry, Susan
    Keen, Corrine
    Mammen, Andrew L.
    Berman, Arlene W.
    Pittaluga, Stefania
    Lepone, Lauren Marissa
    Donahue, Renee Nicole
    Grenga, Italia
    Schlom, Jeffrey
    Hassa, Raffit
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR
    Siu, L.
    Even, C.
    Mesia, R.
    Daste, A.
    Krauss, J.
    Saba, N. F.
    Nabell, L.
    Ready, N. E.
    Brana Garcia, I.
    Kotecki, N.
    Zandberg, D. P.
    Gilbert, J.
    Mehanna, H.
    Jarkowski, A.
    Melillo, G.
    Armstrong, J. M.
    Fayette, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1307 - 1307
  • [34] Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors
    Shen, L.
    Cao, J.
    Gong, J.
    Ji, D.
    Qin, Z.
    Dai, H.
    Wu, K.
    Xu, J.
    Yang, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing (vol 36, pg 633, 2018)
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) : 1645 - 1645
  • [36] MEDI4736, an anti-PD-L1 antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors
    Khleif, S.
    Lutzky, J.
    Segal, N.
    Antonia, S.
    Blake-Haskins, A.
    Stewart, R.
    Robbins, P.
    Shalabi, A.
    Ibrahim, R.
    Wolchok, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S161 - S161
  • [37] Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404)
    Lee, Jung-min
    Zimmer, Alexandra Dos Santos
    Lipkowitz, Stan
    Annunziata, Christina M.
    Ho, Tony Weishiu
    Chiou, Victoria L.
    Minasian, Lori M.
    Houston, Nicole D.
    Ekwede, Irene
    Kohn, Elise C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] A phase II study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab (MEDI4736) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Lee, Sylvia
    Villaflor, Viktoriya
    Haigentz, Missack
    Karyampudi, Kumar
    Tanamly, Susie
    Suzuki, Sam
    Gorbatchevsky, Igor
    Fardis, Maria
    Villaruz, Liza
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)
    Huang, Hui-qiang
    Tao, Rong
    Zou, Liqun
    Cen, Hong
    Guo, Ye
    Huang, Yunhong
    Qian, Wenbin
    Zhang, Liling
    Zhou, Hui
    Yang, Yu
    Yang, Haiyan
    Zhu, Dan
    Fang, Teng
    Dai, Hangjun
    Wang, Yueling
    Yang, Jianxin
    BLOOD, 2019, 134
  • [40] A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).
    Planchard, David
    Shtivelband, Mikhail
    Shi, Kelvin
    Ibrahim, Ramy
    Ballas, Marc
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345